Skip to main content
Toggle navigation
Login
Search
Home
iwCLL X / Twitter
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Tweet
Mark A. Noviski, PhD
Principal Scientist, Cell Biology
Nurix Therapeutics, Inc.
N/A
Poster(s):
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
